Youli Zu
Houston Methodist(US)North China University of Science and Technology(CN)Zhengzhou University(CN)Methodist Hospital(US)Methodist Hospital(US)Gaochun People's Hospital(CN)Stomatological Hospital of Chongqing Medical University(CN)Methodist Hospital(US)Henan Cancer Hospital(CN)First Hospital of Qinhuangdao(CN)Chongqing Medical University(CN)Northwest A&F University(CN)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques
Most-Cited Works
- → MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program(2013)672 cited
- → Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy(2014)524 cited
- → Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins(2013)495 cited
- → Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study(2012)383 cited
- → Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study(2012)357 cited